

## CORRECTION

View Article Online  
View Journal | View Issue



Cite this: *Org. Biomol. Chem.*, 2021, **19**, 486

## Correction: Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF- $\kappa$ B


Yong Ling,<sup>a,b</sup> Zhiqiang Wang,<sup>a,b</sup> Xuemin Wang,<sup>a</sup> Ying Zhao,<sup>a</sup> Wei Zhang,<sup>a</sup> Xinyang Wang,<sup>a</sup> Li Chen,<sup>b,c</sup> Zhangjian Huang<sup>\*b,c</sup> and Yihua Zhang<sup>\*b,c</sup>

DOI: 10.1039/d0ob90173c

rsc.li/obc

Correction for 'Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF- $\kappa$ B' by Yong Ling *et al.*, *Org. Biomol. Chem.*, 2014, **12**, 4517–4530, DOI: 10.1039/C4OB00023D.

The authors regret that there was an incorrect western blot image shown in Fig. 6A representing the Akt group. The correct Fig. 6 is shown below.



**Fig. 6** Immunoblot analysis of the expression and phosphorylation of the Ras-related signal events *in vitro*. (A) SMMC-7721 cells were treated with the vehicle (control), different doses of 5f or FTS were homogenized, and their lysates were subjected to immunoblot analysis using antiphospho-Raf (Ser259), antiphospho-ERK1/2 (Thr202/Tyr204), anti-Akt, antiphospho-Akt (Ser473), anti-phospho-NF- $\kappa$ B p65, anti-NF- $\kappa$ B and anti- $\beta$ -actin antibodies, respectively.  $\beta$ -Actin was used as the control. (B) Quantitative analysis. The relative levels of each signaling event to the control  $\beta$ -actin were determined by densitometric scanning. The data are expressed as means  $\pm$  SD from three duplicate experiments. \* $P$  < 0.01 vs. the control.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>School of Pharmacy, Nantong University, Nantong, 226001, PR China

<sup>b</sup>State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, PR China. E-mail: zyhtgd@163.com, cpudahuang@163.com; Fax: +86-25-83271015; Tel: +86-25-83271015

<sup>c</sup>Center of Drug Discovery, China Pharmaceutical University, Nanjing, 210009, PR China

